PMID- 31322838
OWN - NLM
STAT- MEDLINE
DCOM- 20200423
LR  - 20200423
IS  - 2042-6984 (Electronic)
IS  - 2042-6976 (Linking)
VI  - 9
IP  - 8
DP  - 2019 Aug
TI  - The efficacy and safety of two commercial house dust mite extracts for allergic 
      rhinitis: a head-to-head study.
PG  - 876-882
LID - 10.1002/alr.22343 [doi]
AB  - BACKGROUND: Several studies have demonstrated the efficacy of house dust mite 
      (HDM) immunotherapy in allergic rhinitis (AR). We aimed to compare the efficacy 
      and safety of 2 commercial HDM extracts in a Chinese AR population. METHODS: This 
      was an open-label study. HDM-associated AR patients were randomized into 
      Dermatophagoides pteronyssinus (Dp) extracts (Alutard SQ; ALK, Horsholm, Denmark) 
      and Dp/Dermatophagoides farinae (Df) extracts (NovoHelisen Depot [NHD]; 
      Allergopharma, Reinbek, Germany) groups. All patients received subcutaneous 
      injections for 1 year, and were followed every 3 months during that 1-year 
      period. Symptom score, medication score, and adverse reactions were recorded. The 
      primary endpoint was the total combined symptom and medication score (CSMS) 
      during the efficacy evaluation period. Blood samples were taken for specific 
      immunoglobulin E (IgE), IgG4, and IgE-blocking factor tests at baseline and after 
      the 1-year treatment. RESULTS: A total of 230 AR patients were randomized; 29 
      patients dropped out. Analysis of the primary endpoint demonstrated significant 
      reductions in CSMS of 1.8 vs 3.1 (p < 0.001) in the Alutard group and 1.8 vs 3.3 
      (p < 0.001) in the NHD group compared with baseline. The 2 groups presented equal 
      effectiveness with regard to CSMS, symptom score, and medication score (p > 
      0.05). The treatment was well tolerated in both groups; 17 (14.8%) patients 
      experienced systemic reactions (SRs) in the Alutard group and 13 (11.3%) in the 
      NHD group. The rates of SRs showed no difference in the 2 groups (p > 0.05), and 
      no anaphylaxis occurred. IgG4 and IgE-blocking factor to Dp and Df were increased 
      significantly in both groups after the 1-year treatment. CONCLUSION: Our study 
      confirmed the equal efficacy and safety profile of both commercial extracts in 
      HDM-associated AR patients.
CI  - (c) 2019 ARS-AAOA, LLC.
FAU - Li, Jie
AU  - Li J
AD  - Department of Allergy, Tongji Hospital, Tongji Medical College, Huazhong 
      University of Science and Technology (HUST), Wuhan, China.
FAU - Wu, Yuying
AU  - Wu Y
AD  - Department of Allergy, Tongji Hospital, Tongji Medical College, Huazhong 
      University of Science and Technology (HUST), Wuhan, China.
FAU - Yang, Yongshi
AU  - Yang Y
AD  - Department of Allergy, Tongji Hospital, Tongji Medical College, Huazhong 
      University of Science and Technology (HUST), Wuhan, China.
FAU - Huang, Nan
AU  - Huang N
AD  - Department of Allergy, Tongji Hospital, Tongji Medical College, Huazhong 
      University of Science and Technology (HUST), Wuhan, China.
FAU - Li, Wenjing
AU  - Li W
AD  - Department of Allergy, Tongji Hospital, Tongji Medical College, Huazhong 
      University of Science and Technology (HUST), Wuhan, China.
FAU - Zhang, Shuchen
AU  - Zhang S
AD  - Department of Allergy, Tongji Hospital, Tongji Medical College, Huazhong 
      University of Science and Technology (HUST), Wuhan, China.
FAU - Jiang, Qing
AU  - Jiang Q
AD  - Department of Allergy, Tongji Hospital, Tongji Medical College, Huazhong 
      University of Science and Technology (HUST), Wuhan, China.
FAU - Yang, Lin
AU  - Yang L
AD  - Department of Allergy, Tongji Hospital, Tongji Medical College, Huazhong 
      University of Science and Technology (HUST), Wuhan, China.
FAU - Zhu, Rongfei
AU  - Zhu R
AUID- ORCID: 0000-0003-2103-3381
AD  - Department of Allergy, Tongji Hospital, Tongji Medical College, Huazhong 
      University of Science and Technology (HUST), Wuhan, China.
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
DEP - 20190719
PL  - United States
TA  - Int Forum Allergy Rhinol
JT  - International forum of allergy & rhinology
JID - 101550261
RN  - 0 (Allergens)
RN  - 0 (Antigens, Dermatophagoides)
RN  - 0 (Complex Mixtures)
RN  - 0 (Immunoglobulin G)
RN  - 37341-29-0 (Immunoglobulin E)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Allergens/*administration & dosage
MH  - Animals
MH  - Antigens, Dermatophagoides/*administration & dosage
MH  - Child
MH  - Child, Preschool
MH  - Complex Mixtures/*administration & dosage
MH  - Dermatophagoides farinae/*immunology
MH  - Dermatophagoides pteronyssinus/*immunology
MH  - *Desensitization, Immunologic/adverse effects
MH  - Female
MH  - Humans
MH  - Immunoglobulin E/blood/immunology
MH  - Immunoglobulin G/blood/immunology
MH  - Male
MH  - Rhinitis, Allergic/blood/immunology/*therapy
MH  - Treatment Outcome
MH  - Young Adult
OTO - NOTNLM
OT  - allergens
OT  - allergic rhinitis
OT  - biomarker
OT  - immunotherapy
OT  - rhinitis
EDAT- 2019/07/20 06:00
MHDA- 2020/04/24 06:00
CRDT- 2019/07/20 06:00
PHST- 2018/11/13 00:00 [received]
PHST- 2019/02/09 00:00 [revised]
PHST- 2019/03/26 00:00 [accepted]
PHST- 2019/07/20 06:00 [pubmed]
PHST- 2020/04/24 06:00 [medline]
PHST- 2019/07/20 06:00 [entrez]
AID - 10.1002/alr.22343 [doi]
PST - ppublish
SO  - Int Forum Allergy Rhinol. 2019 Aug;9(8):876-882. doi: 10.1002/alr.22343. Epub 
      2019 Jul 19.